Carbapenem-resistant Enterobacterales standardization across a large health care system

Published:October 20, 2022DOI:


      • Varying definitions of what consitutes a carbapenem-resistant Enterobacterales complicate identification and isolation of patients within the healthcare environment.
      • A crosswalk of definitions was reviewed by a multi-disciplinary workgroup.
      • A standardized definition of CRE was adopted by the system.
      • The electronic medical record was updated to promptly identify patients with carbapenem-resistant Enterobacterales.


      Carbapenem-resistant Enterobacterales (CRE) are multidrug resistant organisms that pose a significant risk in the health care setting. Standardized identification ensures prompt isolation and is imperative to maintain patient safety.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Infection Control
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Centers for Disease Control, Healthcare-associated infections (HAIs), Carbapenem resistant Enterbacterales. Accessed March 30, 2022.

      2. CDC, CRE technical information. Accessed April 1, 2022.

        • CLSI
        Performance standards for antimicrobial susceptibility testing.
        CLSI Guideline M100S. 32th ed. Clinical and Laboratory Standards Institute, Wayne, PA2016
      3. Illinois Department of Health, CRE reporting. Accessed April 4, 2022.